4T1-Luc Cells

4T1-Luc is a genetically engineered variant of the murine 4T1 mammary carcinoma cell line, stably transduced to express a luciferase reporter gene. The parental 4T1 cell line is derived from a spontaneously arising mammary tumor in a mouse and is widely used as a model of stage IV triple-negative breast cancer. It closely mimics human disease in its aggressive growth, poor differentiation, and high metastatic potential, with the ability to spontaneously disseminate from the primary tumor site to distant organs such as lung, liver, bone, and brain. The luciferase-expressing derivative retains these core biological characteristics while enabling non-invasive tracking of tumor progression.

The introduction of the luciferase gene allows for sensitive bioluminescence imaging (BLI) following administration of a luciferin substrate, providing a quantitative and longitudinal readout of tumor burden in live animals. This modification enables real-time monitoring of primary tumor growth, metastatic spread, and therapeutic response without the need for invasive procedures. The luciferase signal correlates with viable cell number, making 4T1-Luciferase particularly useful for in vivo studies of metastasis, tumor kinetics, and drug efficacy in syngeneic immunocompetent mouse models. Stable integration ensures consistent reporter expression across passages, although signal intensity may vary depending on clone selection and experimental conditions.

4T1-Luc maintains the immunological and metastatic properties of the parental line, including resistance to many chemotherapeutic agents and the ability to interact with and modulate the host immune system. This makes it especially valuable for studies of tumor immunology, immune checkpoint therapies, and combination treatment strategies. The addition of a bioluminescent reporter significantly enhances experimental throughput and sensitivity, supporting applications in preclinical drug development, metastatic modeling, and real-time assessment of therapeutic interventions in breast cancer research.